

Letters

RESEARCH LETTER

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Anaphylaxis to the mRNA COVID-19 vaccines is currently estimated to occur in 2.5 to 11.1 cases per million doses, largely in individuals with a history of allergy.¹ Allergic concerns contribute to vaccine hesitancy; we investigated acute allergic reaction incidence after more than 60 000 mRNA COVID-19 vaccine administrations.



Supplemental content

Methods | We prospectively studied Mass General Brigham (MGB) employees who received their first dose of an mRNA COVID-19 vaccine (12/16/2020-2/12/2021, with follow-up through 2/18/2021) (eMethods in the Supplement). For 3 days after vaccination, employees completed symptom surveys through a multipronged approach including email, text message, phone, and smartphone application links. Acute allergic reaction symptoms solicited included itching, rash, hives, swelling, and/or respiratory symptoms (eAppendix in the Supplement).

To identify anaphylaxis, allergists/immunologists reviewed the electronic health records of employees (1) reporting 2 or more allergy symptoms, (2) described as having an allergic reaction in MGB safety reports, (3) logged by the on-call MGB allergy/immunology team supporting employee vaccination, and (4) referred to MGB allergy/immunology. Episodes were scored using the Brighton Criteria² and the

National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria.³ Confirmed anaphylaxis required meeting at least 1 of these 2 sets of criteria.

We described characteristics and outcomes of anaphylaxis cases. We calculated incidence rates and 95% CIs of self-reported acute allergic reactions and confirmed anaphylaxis, using vaccine administrations as the denominator. We compared frequencies using χ^2 tests, considering a 2-sided *P* value of .05 statistically significant. Analyses were conducted in SAS version 9.4. This study was approved by the MGB Human Research Committee with a waiver of informed consent.

Results | Of 64 900 employees who received their first dose of a COVID-19 vaccine, 25 929 (40%) received the Pfizer-BioNTech vaccine and 38 971 (60%) received the Moderna vaccine. At least 1 symptom survey was completed by 52 805 (81%).

Acute allergic reactions were reported by 1365 employees overall (2.10% [95% CI, 1.99%-2.22%]), more frequently with the Moderna vaccine compared with Pfizer-BioNTech (2.20% [95% CI, 2.06%-2.35%] vs 1.95% [95% CI, 1.79%-2.13%]; *P* = .03, **Table 1**). Anaphylaxis was confirmed in 16 employees (0.025% [95% CI, 0.014%-0.040%]): 7 cases from the Pfizer-BioNTech vaccine (0.027% [95% CI, 0.011%-0.056%]) and 9 cases from the Moderna vaccine (0.023% [95% CI, 0.011%-0.044%]) (*P* = .76).

Individuals with anaphylaxis were a mean (SD) age of 41 (13) years, and 15 (94%) were female (**Table 2**); 10 (63%) had a prior allergy history and 5 (31%) had an anaphylaxis history. Mean time to anaphylaxis onset was 17 minutes (SD, 28; range, 1-120). One patient was admitted to intensive care, 9 (56%)

Table 1. Acute Allergic Reactions Self-reported Through Voluntary Reporting and Multipronged Prospective System Surveillance After mRNA COVID-19 Vaccination

| | No. (%) [95% CI] | | | P value |
|--|---------------------------------|------------------------------|-------------------------|---------|
| | Both mRNA vaccines (n = 64 900) | Pfizer-BioNTech (n = 25 929) | Moderna (n = 38 971) | |
| Self-reported allergic reaction ^a | 1365 (2.10) [1.99-2.22] | 506 (1.95) [1.79-2.13] | 859 (2.20) [2.06-2.35] | .03 |
| Confirmed anaphylaxis ^b | | | | |
| Either criteria | 16 (0.025) [0.014-0.040] | 7 (0.027) [0.011-0.056] | 9 (0.023) [0.011-0.044] | .76 |
| Brighton ^c | 14 (0.022) [0.012-0.036] | 7 (0.027) [0.011-0.056] | 7 (0.018) [0.007-0.037] | .44 |
| NIAID/FAAN ^d | 9 (0.014) [0.006-0.026] | 4 (0.015) [0.004-0.040] | 5 (0.012) [0.004-0.030] | .75 |
| Both criteria | 7 (0.011) [0.004-0.022] | 4 (0.015) [0.004-0.040] | 3 (0.008) [0.002-0.023] | .45 |

Abbreviations: mRNA, messenger RNA; NIAID/FAAN, National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network.

^a Itching or rash other than at the injection site (n = 788), respiratory symptoms (n = 342), hives (n = 244), or swelling (n = 191) (see the eAppendix in the Supplement). Numbers do not sum to 1365 because employees could report more than 1 reaction.

^b See Table 2 for details of reactions.

^c The Brighton Collaboration² case definition uses combinations of symptoms to define levels of diagnostic certainty. Brighton level 1 represents the highest level of diagnostic certainty that a reported case represents anaphylaxis; levels 2 and 3 are successively lower levels of diagnostic certainty; level 4 is a case reported as anaphylaxis but that does not meet the Brighton Collaboration

case definition; and level 5 is a case that was neither reported as anaphylaxis nor meets the case definition. This study considered Brighton levels 1 or 2 anaphylaxis cases.

^d NIAID/FAAN clinical criteria³ for the diagnosis of anaphylaxis must meet 1 of the following criteria: (1) acute onset with involvement of skin and/or mucosal tissue and either (a) respiratory compromise or (b) reduced blood pressure or associated symptoms of end organ dysfunction; (2) 2 or more of the following occur after exposure to a likely allergen for that patient: (a) involvement of skin or mucosal tissue, (b) respiratory compromise, (c) reduced blood pressure or associated symptoms, or (d) persistent gastrointestinal symptoms; and (3) reduced blood pressure after exposure to a known allergen for that patient.

Table 2. Anaphylaxis Cases After mRNA COVID-19 Vaccination (n = 16)

| | No. (%) | | |
|--|-----------------------------|-------------------------|---------------------|
| | Both mRNA vaccines (n = 16) | Pfizer-BioNTech (n = 7) | Moderna (n = 9) |
| Age, mean (SD), y | 41 (13) | 41 (14) | 41 (13) |
| Female | 15 (94) | 6 (86) | 9 (100) |
| Prior allergic reactions | 10 (63) | 3 (43) ^a | 7 (78) ^b |
| Prior anaphylaxis | 5 (31) | 1 (14) | 4 (44) |
| Symptoms | | | |
| Pruritus, urticaria, and/or angioedema | 14 (88) | 6 (86) | 8 (89) |
| Sensation of throat closure, cough, wheeze, and/or dyspnea | 14 (88) | 6 (86) | 8 (89) |
| Hypotension and/or tachycardia | 7 (44) | 3 (43) | 4 (44) |
| Nausea, vomiting, and/or diarrhea | 8 (50) | 3 (43) | 5 (56) |
| Minutes to onset, mean (SD) [range] | 17 (28) [1-120] | 14 (7) [10-30] | 19 (38) [1-120] |
| Symptom timing | | | |
| ≤15 min | 14 (88) | 6 (86) | 8 (89) |
| ≤30 min | 15 (94) | 7 (100) | 8 (89) |
| Received epinephrine | 9 (56) | 6 (86) | 3 (33) |
| Treatment setting ^c | | | |
| Emergency department | 9 (56) | 4 (57) | 5 (56) |
| Hospitalization | 1 (6) | 1 (14) | 0 |
| Intensive care unit | 1 (6) | 1 (14) | 0 |
| Brighton level ^d | | | |
| 1 | 1 (6) | 0 | 1 (11) |
| 2 | 13 (81) | 7 (100) | 6 (67) |
| 3 | 2 (13) | 0 | 2 (22) |
| NIAID/FAAN criteria ^e | 9 (56) | 4 (57) | 5 (56) |
| Severity ^f | | | |
| Grade I | 7 (44) | 3 (43) | 4 (44) |
| Grade II | 9 (56) | 4 (57) | 5 (56) |
| Grade III | 0 | 0 | 0 |
| Grade IV | 0 | 0 | 0 |
| Elevated tryptase ^g | 1 (6) | 0 | 1 (11) |

Abbreviations: mRNA, messenger RNA; NIAID/FAAN, National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network.

^a Allergies to (1) dexamethasone and propranolol, (2) penicillin and measles, mumps, and rubella vaccine, and (3) venom, tree nuts, shellfish, aspirin, and sulfites.

^b Allergies to (1) gadolinium, (2) tree nuts and sulfonamide antibiotics, (3) sulfonamide antibiotics and cat dander, (4) peanuts, tree nuts, and morphine, (5) shellfish, tree nuts, and sulfonamide antibiotics, (6) ciprofloxacin, and (7) peanut, penicillin, sulfonamide antibiotics, and gadolinium.

^c Highest level of care reported. There were 3 employees who did not seek treatment, 1 employee who was treated in an urgent care clinic, and 1 employee who was treated in the Mass General Brigham health system vaccine clinic.

^d The Brighton Collaboration² case definition uses combinations of symptoms to define levels of diagnostic certainty. Brighton level 1 represents the highest level of diagnostic certainty that a reported case represents anaphylaxis; levels 2 and 3 are successively lower levels of diagnostic certainty; level 4 is a case reported as anaphylaxis but that does not meet the Brighton Collaboration case definition; and level 5 is a case that was neither reported as anaphylaxis

nor meets the case definition. This study considered only Brighton level 1 or 2 as anaphylaxis cases. Brighton level 3 cases met NIAID/FAAN clinical criteria.³

^e NIAID/FAAN clinical criteria³ for the diagnosis of anaphylaxis must meet 1 of the following criteria: (1) acute onset with involvement of skin and/or mucosal tissue and either (a) respiratory compromise or (b) reduced blood pressure or associated symptoms of end organ dysfunction; (2) 2 or more of the following occur after exposure to a likely allergen for that patient: (a) involvement of skin or mucosal tissue, (b) respiratory compromise, (c) reduced blood pressure or associated symptoms, or (d) persistent gastrointestinal symptoms; and (3) reduced blood pressure after exposure to a known allergen for that patient.

^f Grade I, cutaneous symptoms; grade II, measurable but not life-threatening symptoms; grade III, life-threatening symptoms; grade IV, cardiac and/or respiratory arrest. Based on a scale of anaphylactoid reactions in *Lancet*. 1977;1(8009):466-469.

^g Tryptase was captured acutely in 5 (32%) cases. An elevated tryptase level was defined as either above the upper limit of normal or $>(2 + 1.2 \times \text{baseline tryptase level})$. One patient with a baseline tryptase of 4.3 ng/mL had an acute tryptase of 7.7 ng/mL associated with Moderna vaccine anaphylaxis.

received intramuscular epinephrine, and all recovered. Three employees, with prior anaphylaxis history, did not seek care.

Discussion | In this prospective cohort of health care employees, 98% did not have any symptoms of an allergic reaction after receiving an mRNA COVID-19 vaccine. The remaining 2%

reported some allergic symptoms; however, severe reactions consistent with anaphylaxis occurred at a rate of 2.47 per 10 000 vaccinations. All individuals with anaphylaxis cases recovered without shock or endotracheal intubation.

The incidence rate of confirmed anaphylaxis in this study is larger than that reported by the Centers for Disease Control

and Prevention based on passive spontaneous reporting methods (0.025-0.11/10 000 vaccinations).¹ However, the overall risk of anaphylaxis to an mRNA COVID-19 vaccine remains extremely low and largely comparable to other common health care exposures.⁴ Although cases were clinically compatible with anaphylaxis, the mechanism of these reactions is unknown.

Most of the vaccine recipients with anaphylaxis had allergy histories, with 31% having prior anaphylaxis. However, given that approximately 5% of adults have severe food allergy histories⁵ and 1% of adults have severe drug allergy histories,⁶ this MGB employee cohort likely included almost 4000 individuals with severe food or medication allergy histories who were safely vaccinated.

Limitations of this study include the use of self-reported data. However, cohort participants were largely health care workers, and therefore self-report data reliability may be high. The use of vaccine administrations as the denominator for allergic reaction incidence may have resulted in some inaccuracy. Although study methods might have missed cases of potential anaphylaxis, comprehensive prospective surveillance methods were used, and symptom survey alone captured 81% of all vaccinated employees. A northeastern US cohort may not be generalizable.

Kimberly G. Blumenthal, MD, MSc
Lacey B. Robinson, MD, MPH
Carlos A. Camargo Jr, MD, DrPH
Erica S. Shenoy, MD, PhD
Aleena Banerji, MD
Adam B. Landman, MD
Paige Wickner, MD, MPH

Author Affiliations: Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston (Blumenthal, Robinson, Banerji); Department of Emergency Medicine, Massachusetts General Hospital, Boston (Camargo); Division of Infectious Diseases, Massachusetts General Hospital, Boston (Shenoy); Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts (Landman); Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts (Wickner).

Corresponding Author: Kimberly G. Blumenthal, MD, MSc, The Mongan Institute, Massachusetts General Hospital, 100 Cambridge St, 16th Floor, Boston, MA 02114 (kblumenthal@mgh.harvard.edu).

Accepted for Publication: March 2, 2021.

Published Online: March 8, 2021. doi:[10.1001/jama.2021.3976](https://doi.org/10.1001/jama.2021.3976)

Author Contributions: Dr Blumenthal had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Landman and Wickner are co-senior authors.

Concept and design: Blumenthal, Robinson, Camargo, Banerji, Landman, Wickner.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Blumenthal.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Blumenthal.

Obtained funding: Blumenthal.

Administrative, technical, or material support: Blumenthal, Banerji, Landman, Wickner.

Supervision: Blumenthal, Shenoy, Landman, Wickner.

Conflict of Interest Disclosures: Dr Blumenthal reports receiving grants from the American Academy of Allergy Asthma and Immunology (AAAAI) Foundation, CRICO, and Massachusetts General Hospital, outside the submitted work. Dr Camargo reports receiving grants from the National Institutes of Health (NIH) outside the submitted work. Dr Landman reports receiving personal fees from Abbott Medical Device Cybersecurity Council, outside the submitted work. Dr Wickner reports receiving grants from CRICO, outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by NIH KO1 AI125631 and the Massachusetts General Hospital Department of Medicine Transformative Scholar Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH nor Massachusetts General Hospital.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank many colleagues in the Mass General Brigham health system for the design and implementation of the COVID-19 vaccination program, including Dean M. Hashimoto, MD, Paul D. Biddinger, MD, Thomas D. Sequist, MD, MPH, Upeka Samarakoon, MS, PhD, MPH, Rajesh Patel, MD, MPH, Leeann Ouimet, MBA, Allen Judd, AB, Anna R. Wolfson, MD, Rebecca Saff, MD, PhD, Aidan A. Long, MD, Lily Li, MD, Tanya M. Laidlaw, MD, David I. Hong, MD, Anna M. Feldweg, MD, Katrin Stinson, MPH, Amanda J. Centi, PhD, Lynn Simpson, MPH, Nahal Beik, PharmD, BCPS, Christian M. Mancini, BS, Amelia S. Cogan, MPH, and Aubree E. McMahon, BA. We thank Xiaoqing Fu, MS, for assistance with data analysis. No compensation was received by any of these individuals.

- Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020–January 18, 2021. *JAMA*. Published online February 12, 2021. doi:[10.1001/jama.2021.1967](https://doi.org/10.1001/jama.2021.1967)
- Rüggeberg JU, Gold MS, Bayas JM, et al; Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5675-5684. doi:[10.1016/j.vaccine.2007.02.064](https://doi.org/10.1016/j.vaccine.2007.02.064)
- Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol*. 2006;117(2):391-397. doi:[10.1016/j.jaci.2005.12.1303](https://doi.org/10.1016/j.jaci.2005.12.1303)
- Kim MH, Lee SY, Lee SE, et al. Anaphylaxis to iodinated contrast media: clinical characteristics related with development of anaphylactic shock. *PLoS One*. 2014;9(6):e100154. doi:[10.1371/journal.pone.0100154](https://doi.org/10.1371/journal.pone.0100154)
- Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. *JAMA Netw Open*. 2019;2(1):e185630. doi:[10.1001/jamanetworkopen.2018.5630](https://doi.org/10.1001/jamanetworkopen.2018.5630)
- Dhopeshwarkar N, Sheikh A, Doan R, et al. Drug-induced anaphylaxis documented in electronic health records. *J Allergy Clin Immunol Pract*. 2019;7(1):103-111. doi:[10.1016/j.jaip.2018.06.010](https://doi.org/10.1016/j.jaip.2018.06.010)